New Abbott data revealed at meeting

LIBERTYVILLE TOWNSHIP -- Two studies show that in patients with multiple lipid problems, Abbott's ABT-335 combined with two commonly prescribed statins significantly improved three key lipids -- LDL "bad" cholesterol, triglycerides and HDL "good" cholesterol -- compared to the corresponding monotherapies. Results were presented Monday at the American College of Cardiology's 57th annual Scientific Sessions in Chicago. ABT-335, an investigational new fenofibric acid molecule, will be known as TriLipix.